Haleon plc is anticipated to report Q3 2026 revenue of £2.93 billion and adjusted diluted EPS of £0.057, with the stock currently trading at £3.82 compared to an average analyst price target of £4.13.
Investors are primarily focused on the company's Organic Revenue Growth (ORG), specifically whether growth is increasingly driven by volume gains rather than just price increases.
The company previously maintained its full-year 2026 organic growth guidance of 3-5% following H1 results, though analysts note that hitting the upper end requires a strong cough-and-cold season. Performance in Oral Health, particularly the Sensodyne brand, remains a key driver of market share gains in North America and emerging markets.